Tuesday, 15 September 2015

Potassium Channel Blockers

http://www.oncotherapynetwork.com/central-nervous-system-cancer-targets/potassium-channel-blockers-show-promise-treatment-brain-tumors?GUID=027DE295-0400-4A2D-85EA-A43E10BF48F7&rememberme=1&ts=15092015

Not specific to GBM's but of interest

3 comments:

  1. Yes, of interest. Thioridazine was also tested in a subcutaneous GBM mouse model recently.

    "Identification of thioridazine, an antipsychotic drug, as an antiglioblastoma and anticancer stem cell agent using public gene expression data"
    http://www.ncbi.nlm.nih.gov/pubmed/25950483

    The usual limitations apply in this glioma study: subcutaneous tumor implant rather than intracranial, intraperitoneal injection of the drug rather than oral application, the decades-old U87 cell line used in vivo rather than a low-passage patient-derived line. Still, thioridazine seems to keep coming up in glioma studies, and I'll be keeping an eye on this.

    ReplyDelete
  2. DOPAMINE ADDICTION IN GLIOBLASTOMA
    MULTIFORME DURING CHEMOTHERAPY IS MEDIATED BY A
    DRD2/beta-ARRESTIN/AKT SIGNALING COMPLEX

    http://neuro-oncology.oxfordjournals.org/content/16/suppl_5/v65.4.abstract

    Here the mechanism of action of thioridazine is not potassium-channel blocking but dopamine receptor inhibition.

    ReplyDelete
  3. And from this year's ASCO:

    Targeting dopamine receptor 2 (DRD2) signaling in combination with temozolomide chemotherapy as a novel therapeutic concept in glioblastomas.

    http://meetinglibrary.asco.org/content/152566-156

    In which thioridazine improves TMZ sensitivity in an intracranial GBM mouse model. I would certainly like to see the poster for this if anyone finds it.

    ReplyDelete